406 related articles for article (PubMed ID: 27105119)
1. Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition.
Kazlauskiene M; Tamulaitis G; Kostiuk G; Venclovas Č; Siksnys V
Mol Cell; 2016 Apr; 62(2):295-306. PubMed ID: 27105119
[TBL] [Abstract][Full Text] [Related]
2. Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity.
Jia N; Mo CY; Wang C; Eng ET; Marraffini LA; Patel DJ
Mol Cell; 2019 Jan; 73(2):264-277.e5. PubMed ID: 30503773
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of Cas10 Govern Discrimination between Self and Non-self in Type III CRISPR-Cas Immunity.
Wang L; Mo CY; Wasserman MR; Rostøl JT; Marraffini LA; Liu S
Mol Cell; 2019 Jan; 73(2):278-290.e4. PubMed ID: 30503774
[TBL] [Abstract][Full Text] [Related]
4. Genetic Dissection of the Type III-A CRISPR-Cas System Csm Complex Reveals Roles of Individual Subunits.
Mogila I; Kazlauskiene M; Valinskyte S; Tamulaitiene G; Tamulaitis G; Siksnys V
Cell Rep; 2019 Mar; 26(10):2753-2765.e4. PubMed ID: 30840895
[TBL] [Abstract][Full Text] [Related]
5. Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus.
Tamulaitis G; Kazlauskiene M; Manakova E; Venclovas Č; Nwokeoji AO; Dickman MJ; Horvath P; Siksnys V
Mol Cell; 2014 Nov; 56(4):506-17. PubMed ID: 25458845
[TBL] [Abstract][Full Text] [Related]
6. A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems.
Kazlauskiene M; Kostiuk G; Venclovas Č; Tamulaitis G; Siksnys V
Science; 2017 Aug; 357(6351):605-609. PubMed ID: 28663439
[TBL] [Abstract][Full Text] [Related]
7. A jumbo phage that forms a nucleus-like structure evades CRISPR-Cas DNA targeting but is vulnerable to type III RNA-based immunity.
Malone LM; Warring SL; Jackson SA; Warnecke C; Gardner PP; Gumy LF; Fineran PC
Nat Microbiol; 2020 Jan; 5(1):48-55. PubMed ID: 31819217
[TBL] [Abstract][Full Text] [Related]
8. crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus.
Karvelis T; Gasiunas G; Miksys A; Barrangou R; Horvath P; Siksnys V
RNA Biol; 2013 May; 10(5):841-51. PubMed ID: 23535272
[TBL] [Abstract][Full Text] [Related]
9. Adaptation in bacterial CRISPR-Cas immunity can be driven by defective phages.
Hynes AP; Villion M; Moineau S
Nat Commun; 2014 Jul; 5():4399. PubMed ID: 25056268
[TBL] [Abstract][Full Text] [Related]
10. Mutations in Cas9 Enhance the Rate of Acquisition of Viral Spacer Sequences during the CRISPR-Cas Immune Response.
Heler R; Wright AV; Vucelja M; Bikard D; Doudna JA; Marraffini LA
Mol Cell; 2017 Jan; 65(1):168-175. PubMed ID: 28017588
[TBL] [Abstract][Full Text] [Related]
11. Cas3 is a limiting factor for CRISPR-Cas immunity in Escherichia coli cells lacking H-NS.
Majsec K; Bolt EL; Ivančić-Baće I
BMC Microbiol; 2016 Mar; 16():28. PubMed ID: 26956996
[TBL] [Abstract][Full Text] [Related]
12. The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.
Foster K; Kalter J; Woodside W; Terns RM; Terns MP
RNA Biol; 2019 Apr; 16(4):449-460. PubMed ID: 29995577
[TBL] [Abstract][Full Text] [Related]
13. Degradation of Phage Transcripts by CRISPR-Associated RNases Enables Type III CRISPR-Cas Immunity.
Jiang W; Samai P; Marraffini LA
Cell; 2016 Feb; 164(4):710-21. PubMed ID: 26853474
[TBL] [Abstract][Full Text] [Related]
14. CRISPR Immunological Memory Requires a Host Factor for Specificity.
Nuñez JK; Bai L; Harrington LB; Hinder TL; Doudna JA
Mol Cell; 2016 Jun; 62(6):824-833. PubMed ID: 27211867
[TBL] [Abstract][Full Text] [Related]
15. Programmable DNA cleavage in vitro by Cas9.
Karvelis T; Gasiunas G; Siksnys V
Biochem Soc Trans; 2013 Dec; 41(6):1401-6. PubMed ID: 24256227
[TBL] [Abstract][Full Text] [Related]
16. RNA and DNA Targeting by a Reconstituted Thermus thermophilus Type III-A CRISPR-Cas System.
Liu TY; Iavarone AT; Doudna JA
PLoS One; 2017; 12(1):e0170552. PubMed ID: 28114398
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas systems exploit viral DNA injection to establish and maintain adaptive immunity.
Modell JW; Jiang W; Marraffini LA
Nature; 2017 Apr; 544(7648):101-104. PubMed ID: 28355179
[TBL] [Abstract][Full Text] [Related]
18. DNA targeting by subtype I-D CRISPR-Cas shows type I and type III features.
Lin J; Fuglsang A; Kjeldsen AL; Sun K; Bhoobalan-Chitty Y; Peng X
Nucleic Acids Res; 2020 Oct; 48(18):10470-10478. PubMed ID: 32960267
[TBL] [Abstract][Full Text] [Related]
19. Unique properties of spacer acquisition by the type III-A CRISPR-Cas system.
Zhang X; Garrett S; Graveley BR; Terns MP
Nucleic Acids Res; 2022 Feb; 50(3):1562-1582. PubMed ID: 34893878
[TBL] [Abstract][Full Text] [Related]
20. Two distinct DNA binding modes guide dual roles of a CRISPR-Cas protein complex.
Blosser TR; Loeff L; Westra ER; Vlot M; Künne T; Sobota M; Dekker C; Brouns SJJ; Joo C
Mol Cell; 2015 Apr; 58(1):60-70. PubMed ID: 25752578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
